UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ ☒	Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

	for the Quarterly Period Ended ~~June~~September 30, 2022

or☐

☐	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period from to

	~~for the Transition Period from _____________ to _____________~~

Commission File Number 001-32982

Atrion Corporation
(Exact Name of Registrant as Specified in its Charter)

Delaware		63-0821819
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

One Allentown Parkway, Allen, Texas 75002
(Address of Principal Executive Offices) ~~(Zip~~(Zip Code)

(972) 390-9800
(~~Registrant’s~~Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol

Name of each exchange

on which registered

Common stock, Par Value $0.10 per share

ATRI

The Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒☒ Yes ☐☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Registration S-T (§(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒☒ Yes ☐☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of ~~“large~~“large accelerated filer,~~” “accelerated~~” “accelerated filer,~~” “smaller~~” “smaller reporting company,”” and ~~“emerging~~“emerging growth ~~company”~~company” in Rule 12b-2 of the Exchange Act.

Large ~~Accelerated~~accelerated Filer	☒☒	Accelerated filer	☐☐
Non-accelerated filer	☐☐	Smaller reporting company	☐☐
		Emerging growth company	☐☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐☐ Yes ☒☒ No

Indicate the number of shares outstanding of each of the ~~issuer’s~~issuer’s classes of common stock, as of the latest practicable date.

Title of Each Class

Number of Shares Outstanding at

~~July 29,~~October 28, 2022

Common stock, Par Value $0.10 per share

~~1,785,989~~1,772,622

ATRION CORPORATION AND SUBSIDIARIES

TABLE OF CONTENTS

PART I.	Financial Information		3

Item 1.	Financial Statements		34

	Condensed Consolidated Statements of Income (Unaudited) For the Three and Nine Months Ended ~~June~~September 30, 2022 and ~~June~~September 30, 2021		4

	Condensed Consolidated Balance Sheets (Unaudited) ~~June~~September 30, 2022 and December 31, ~~2021~~		4

	~~Condensed Consolidated Statements of Cash Flows (Unaudited) For the Three Months Ended June 30, 2022 and June 30,~~ 2021		5

	Condensed Consolidated Statements of Cash Flows (Unaudited) For the Nine Months Ended September 30, 2022 and 2021		6

	Condensed Consolidated Statements of Changes in ~~Stockholders’~~Stockholders’ Equity (Unaudited) For the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2022 and ~~June 30,~~ 2021		67

	Notes to Condensed Consolidated Financial Statements (Unaudited)		89

Item 2.	~~Management’s~~Management's Discussion and Analysis of Financial Condition and Results of Operations		1415

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		1819

Item 4.	Controls and Procedures		1819

PART II.	Other Information		1920

Item 1.	Legal Proceedings		1920

Item 1A.	Risk Factors		1920

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		1920

Item 6.	Exhibits		2021

SIGNATURES		21	22

Table of Contents

PART I

FINANCIAL INFORMATION

~~Item 1. Financial Statements.~~

~~ATRION CORPORATION AND SUBSIDIARIES~~

~~CONDENSED CONSOLIDATED STATEMENTS OF INCOME~~

~~(Unaudited)~~

Three Months Ended
June 30,

Six Months Ended
June 30,

2022

2021

2022

2021

(in thousands, except per share amounts)

(in thousands, except per share amounts)

Revenues

$ 48,882

$ 42,693

$ 96,020

$ 81,862

Cost of goods sold

28,049

24,826

55,943

47,656

Gross profit

20,833

17,867

40,077

34,206

Operating expenses:

Selling

2,629

1,874

5,146

3,800

General and administrative

5,622

4,753

10,723

8,925

Research and development

1,553

1,445

2,929

2,755

9,804

8,072

18,798

15,480

Operating income

11,029

9,795

21,279

18,726

Interest and dividend income

292

183

429

399

Other investment income/(losses)

(308 )

963

(548 )

1,025

Other income

60

0

85

66

44

1,146

(34 )

1,490

Income before provision for income taxes

11,073

10,941

21,245

20,216

Provision for income taxes

(1,725 )

(2,016 )

(3,398 )

(3,565 )

Net income

$ 9,348

$ 8,925

$ 17,847

$ 16,651

Net income per basic share

$ 5.21

$ 4.89

$ 9.94

$ 9.12

Weighted average basic shares outstanding

1,794

1,826

1,796

1,826

Net income per diluted share

$ 5.20

$ 4.88

$ 9.91

$ 9.10

Weighted average diluted shares outstanding

1,798

1,828

1,800

1,830

Dividends per common share

$ 1.95

$ 1.75

$ 3.90

$ 3.50

~~The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.~~

Table of Contents

Item 1. Financial Statements.

ATRION CORPORATION AND SUBSIDIARIES

~~CONDENSED CONSOLIDATED BALANCE SHEETS~~

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

June 30,
2022

December 31,
2021

Assets

(in thousands)

Current assets:

Cash and cash equivalents

$ 16,437

$ 32,264

Short-term investments

34,146

29,059

Accounts receivable

27,539

21,023

Inventories

54,281

50,778

Prepaid expenses and other current assets

5,171

3,447

137,574

136,571

Long-term investments

15,794

19,423

Property, plant and equipment

249,648

233,217

Less accumulated depreciation and amortization

140,842

135,245

108,806

97,972

Other assets and deferred charges:

Patents

1,242

1,302

Goodwill

9,730

9,730

Other

2,171

2,266

13,143

13,298

Total assets

$ 275,317

$ 267,264

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable and accrued liabilities

$ 17,861

$ 13,076

Accrued income and other taxes

1,412

270

19,273

13,346

Line of credit

0

0

Other non-current liabilities

9,589

9,622

Stockholders’ equity:

Common stock, par value $0.10 per share; authorized 10,000 shares, issued 3,420 shares

342

342

Paid-in capital

66,167

61,174

Retained earnings

368,165

357,324

Treasury shares, 1,632 at June 30, 2022 and 1,619 at December 31, 2021, at cost

(188,219 )

(174,544 )
Total stockholders’ equity

246,455

244,296

Total liabilities and stockholders’ equity

$ 275,317

$ 267,264

	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
	(in thousands, except per share amounts)						(in thousands, except per share amounts)

Revenues	$	44,631		$	42,855		$	140,651		$	124,716
Cost of goods sold		26,978			25,065			82,921			72,720
Gross profit		17,653			17,790			57,730			51,996
Operating expenses:
Selling		2,306			2,081			7,451			5,882
General and administrative		4,493			4,838			15,217			13,763
Research and development		1,251			1,393			4,180			4,147
		8,050			8,312			26,848			23,792
Operating income		9,603			9,478			30,882			28,204

Interest and dividend income		210			281			639			680
Other investment income/(losses)		764			(173	)		216			852
Other income		7			-			92			67
		981			108			947			1,599

Income before provision for income taxes		10584			9,586			31,829			29,803
Provision for income taxes		(1,745	)		(1,309	)		(5,143	)		(4,875	)

Net income	$	8,839		$	8,277		$	26,686		$	24,928

Net income per basic share	$	4.95		$	4.59		$	14.89		$	13.71
Weighted average basic shares outstanding		1,786			1,803			1,793			1,818

Net income per diluted share	$	4.94		$	4.58		$	14.86		$	13.68
Weighted average diluted shares outstanding		1,788			1,806			1,796			1,822

Dividends per common share	$	2.15		$	1.95		$	6.05		$	5.45

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

ATRION CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED ~~STATEMENTS OF CASH FLOWS~~BALANCE SHEETS

(Unaudited)

Six Months Ended
June 30,

2022

2021

(In thousands)

Cash flows from operating activities:

Net income

$ 17,847

$ 16,651

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

6,866

6,210

Deferred income taxes

(535 )

1,092

Stock-based compensation

1,321

1,338

Net change in unrealized gains and losses on investments

475

(1,024 )
Net change in accrued interest, premiums, and discounts on investments

202

269

Other

0

25

26,176

24,561

Changes in operating assets and liabilities:

Accounts receivable

(6,516 )

(6,237 )
Inventories

(3,503 )

2,573

Prepaid expenses

(2,201 )

(4,006 )
Other non-current assets

573

12

Accounts payable and accrued liabilities

2,165

(1,454 )
Accrued income and other taxes

1,141

234

Other non-current liabilities

502

345

Cash flows from operating activities

18,337

16,028

Cash flows from investing activities:

Property, plant and equipment additions

(15,247 )

(7,252 )
Purchase of investments

(22,322 )

(16,110 )
Proceeds from sale of investments

208

166

Proceeds from maturities of investments

19,978

19,246

Cash flows from investing activities

(17,383 )

(3,950 )

Cash flows from financing activities:

Purchase of treasury stock

(9,340 )

(10,488 )
Shares tendered for employees’ withholding taxes on stock-based compensation

(454 )

(585 )
Dividends paid

(6,987 )

(6,385 )
Cash flows from financing activities

(16,781 )

(17,458 )

Net change in cash and cash equivalents

(15,827 )

(5,380 )
Cash and cash equivalents at beginning of period

32,264

22,450

Cash and cash equivalents at end of period

$ 16,437

$ 17,070

Cash paid for:

Income taxes

$ 3,952

$ 5,095

Non-cash financing activities:

Non-cash effect of stock option exercises

$ 4,008

$ 6,012

~~The accompanying notes to the condensed consolidated financial statements are an integral part of these statements~~

~~Table of Contents~~

~~ATRION CORPORATION AND SUBSIDIARIES~~

~~CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY~~

~~(Unaudited)~~

For the Three Months Ended

Common Stock

Treasury Stock

Additional

Shares

Paid-in

Retained

Outstanding

Amount

Shares

Amount

Capital

Earnings

Total

Balances, April 1, 2021

1,827

$ 342

1,593

$ (157,572 )

$ 59,760

$ 342,221

$ 244,751

Net income

8,925

8,925

Stock-based compensation transactions

1

(1 )

15

710

725

Purchase of treasury stock

(17 )

17

(10,488 )

(10,488 )
Dividends

(3,192 )

(3,192 )
Balances, June 30, 2021

1,811

$ 342

1,609

$ (168,045 )

$ 60,470

$ 347,954

$ 240,721

Balances, April 1, 2022

1,795

$ 342

1,625

$ (177,985 )

$ 61,560

$ 362,313

$ 246,230

Net income

9,348

9,348

Stock-based compensation transactions

3

(3 )

(3,887 )

4,607

720

Shares surrendered in stock transactions

(1 )

1

(454 )

(454 )
Purchase of treasury stock

(9 )

9

(5,893 )

(5,893 )
Dividends

(3,496 )

(3,496 )
Balances, June 30, 2022

1,788

$ 342

1,632

$ (188,219 )

$ 66,167

$ 368,165

$ 246,455

	September 30, 2022			December 31, 2021
Assets	(in thousands)
Current assets:
Cash and cash equivalents	$	27,125		$	32,264
Short-term investments		20,296			29,059
Accounts receivable		22,038			21,023
Inventories		59,624			50,778
Prepaid expenses and other current assets		3,598			3,447
		132,681			136,571

Long-term investments		11,133			19,423

Property, plant and equipment		258,970			233,217
Less: accumulated depreciation and amortization		143,857			135,245
		115,113			97,972

Other assets and deferred charges:
Patents and licenses		1,213			1,302
Goodwill		9,730			9,730
Other		2,084			2,266
		13,027			13,298

Total assets	$	271,954		$	267,264

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities	$	15,085		$	13,076
Accrued income and other taxes		2,794			270
		17,879			13,346

Line of credit		-			-

Other non-current liabilities		7,800			9,622

Stockholders’ equity:
Common stock, par value $0.10 per share; authorized 10,000 shares, issued 3,420 shares		342			342
Additional paid-in capital		66,244			61,174
Retained earnings		373,163			357,324
Treasury shares, 1,640 at September 30, 2022 and 1,619 at December 31, 2021, at cost		(193,474	)		(174,544	)
Total stockholders’ equity		246,275			244,296


Total liabilities and stockholders’ equity	$	271,954		$	267,264

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

ATRION CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Nine Months Ended September 30,
	2022			2021
	(in thousands)
Cash flows from operating activities:
Net income	$	26,686		$	24,928
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		10,339			9,527
Deferred income taxes		(2,391	)		1,613
Stock-based compensation		1,523			1,766
Net change in unrealized gains and losses on investments		(289	)		(853	)
Net change in accrued interest, premiums, and discounts on investments		219			385
Other		-			24
		36,087			37,390

Changes in operating assets and liabilities:
Accounts receivable		(1,015	)		(8,776	)
Inventories		(8,846	)		2,991
Prepaid expenses		(575	)		(4,125	)
Other non-current assets		606			138
Accounts payable and accrued liabilities		(403	)		326
Accrued income and other taxes		2,523			466
Other non-current liabilities		570			415
Cash flows from operating activities		28,947			28,825

Cash flows from investing activities:
Property, plant and equipment additions		(25,321	)		(11,596	)
Purchase of investments		(25,544	)		(18,110	)
Proceeds from sale of investments		240			165
Proceeds from maturities of investments		42,426			29,391
Cash flows from investing activities		(8,199	)		(150	)

Cash flows from financing activities:
Purchase of treasury stock		(14,430	)		(16,988	)
Shares tendered for employees’ withholding taxes on stock-based compensation		(633	)		(585	)
Dividends paid		(10,824	)		(9,896	)
Cash flows from financing activities		(25,887	)		(27,469	)

Net change in cash and cash equivalents		(5,139	)		1,206
Cash and cash equivalents at beginning of period		32,264			22,450
Cash and cash equivalents at end of period	$	27,125		$	23,656

Cash paid for:
Income taxes	$	5,786		$	5,540

Non-cash financing activities:
Non-cash effect of stock option exercises	$	4,008		$	6,012

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements

Table of Contents

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN ~~STOCKHOLDERS’~~STOCKHOLDERS’ EQUITY

(Unaudited)

For the Six Months Ended
For the Three Months Ended																				For the Three Months Ended
	Common Stock					Treasury Stock						Additional									Common Stock					Treasury Stock						Additional Paid-in		Retained
	Shares											Paid-in		Retained							Shares			Amount		Shares			Amount			Capital		Earnings			Total
Balances, July 1, 2021																						1,811		$	342		1,609		$	(168,045	)	$	60,470	$	347,954		$	240,721
	Outstanding			Amount		Shares			Amount			Capital		Earnings			Total
Balances, January 1, 2021		1,826		$	342		1,594		$	(151,127	)	$	53,527	$	337,700		$	240,442
Net income																																			8,277			8,277
Stock-based compensation transactions																						1					(1	)		1			294					295
Purchase of treasury stock																						(11	)				11			(6,500	)							(6,500	)
Dividends																																			(3,514	)		(3,514	)
Balances, September 30, 2021																						1,801		$	342		1,619		$	(174,544	)	$	60,764	$	352,717		$	239,279

Balances, July 1, 2022																						1,788		$	342		1,632		$	(188,219	)	$	66,167	$	368,165		$	246,455

Net income															16,651			16,651																	8,839			8,839
Stock-based compensation transactions		3					(3	)		(5,845	)		6,943					1,098				1					(1	)		14			77					91
Shares surrendered in stock transactions		(1	)				1			(585	)							(585	)											(179	)							(179	)
Purchase of treasury stock		(17	)				17			(10,488	)							(10,488	)			(9	)				9			(5,090	)							(5,090	)
Dividends															(6,397	)		(6,397	)																(3,841	)		(3,841	)
Balances, June 30, 2021		1,811		$	342		1,609		$	(168,045	)	$	60,470	$	347,954		$	240,721

Balances, January 1, 2022		1,801		$	342		1,619		$	(174,544	)	$	61,174	$	357,324		$	244,296

Net income															17,847			17,847
Stock-based compensation transactions		3					(3	)		(3,881	)		4,993					1,112
Shares surrendered in stock transactions		(1	)				1			(454	)							(454	)
Purchase of Treasury Stock		(15	)				15			(9,340	)							(9,340	)
Dividends															(7,006	)		(7,006	)
Balances, June 30, 2022		1,788		$	342		1,632		$	(188,219	)	$	66,167	$	368,165		$	246,455
Balances, September 30, 2022																						1,780		$	342		1,640		$	(193,474	)	$	66,244	$	373,163		$	246,275

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

For the Nine Months Ended
	Common Stock					Treasury Stock						Additional Paid-in		Retained
	Shares			Amount		Shares			Amount			Capital		Earnings			Total
Balances, January 1, 2021		1,826		$	342		1,594		$	(151,127	)	$	53,527	$	337,700		$	240,442

Net income															24,928			24,928
Stock-based compensation transactions		4					(4	)		(5,844	)		7,237					1,393
Shares surrendered in stock transactions		(1	)				1			(585	)							(585	)
Purchase of treasury stock		(28	)				28			(16,988	)							(16,988	)
Dividends															(9,911	)		(9,911	)
Balances, September 30, 2021		1,801		$	342		1,619		$	(174,544	)	$	60,764	$	352,717		$	239,279

Balances, January 1, 2022		1,801		$	342		1,619		$	(174,544	)	$	61,174	$	357,324		$	244,296

Net income															26,686			26,686
Stock-based compensation transactions		4					(4	)		(3,867	)		5,070					1,203
Shares surrendered in stock transactions		(1	)				1			(633	)							(633	)
Purchase of Treasury Stock		(24	)				24			(14,430	)							(14,430	)
Dividends															(10,847	)		(10,847	)
Balances, September 30, 2022		1,780		$	342		1,640		$	(193,474	)	$	66,244	$	373,163		$	246,275

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

Table of Contents

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Atrion Corporation and its subsidiaries (collectively referred to herein as ~~“Atrion,”~~“Atrion,” the ~~“Company,” “we,” “our,”~~“Company,” “we,” “our,” or ~~“us”~~“us”) have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, these statements include all normal and recurring adjustments necessary to present a fair statement of our consolidated results of operations, financial position, and cash flows. Certain prior-year balances have been reclassified in order to conform to the current year presentation. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. Preparation of the ~~Company’s~~Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that can have a significant impact on our revenue, operating income, and net income, as well as on the value of certain assets and liabilities on our consolidated balance sheets. We base our assumptions, judgments, and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. We are not aware of any specific event or circumstance that would require updates to our estimates or judgments or require us to revise the carrying value of our assets or liabilities as of ~~August~~November 8, 2022, the date of issuance of this Quarterly Report on Form 10-Q. However, these estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. At least quarterly, we evaluate our assumptions, judgments, and estimates and make changes as we deem necessary.

This Quarterly Report on Form 10-Q should be read in conjunction with the ~~Company’s~~Company’s consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (“("2021 Form ~~10-K”~~10-K").

(2) Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined by using the first-in, first-out method. The following table details the major components of inventories (in thousands):

	June 30,		December 31,		September 30,		December 31,
	2022		2021		2022		2021
Raw materials	$	26,888	$	23,733	$	30,248	$	23,733
Work in process		11,591		9,571		13,290		9,571
Finished goods		15,802		17,474		16,086		17,474
Total inventories	$	54,281	$	50,778	$	59,624	$	50,778

Table of Contents

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(3) Income per share

The following is the computation for basic and diluted income per share:

	Three Months ended June 30,				Six Months ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021		2022		2021		2022		2021
	(in thousands, except per share amounts)								(in thousands, except per share amounts)
Net income	$	9,348	$	8,925	$	17,847	$	16,651	$	8,839	$	8,277	$	26,686	$	24,928
Weighted average basic shares outstanding		1,794		1,826		1,796		1,826		1,786		1,803		1,793		1,818
Add: Effect of dilutive securities		4		2		4		4		2		3		3		4
Weighted average diluted shares outstanding		1,798		1,828		1,800		1,830		1,788		1,806		1,796		1,822
Earnings per share:
Basic	$	5.21	$	4.89	$	9.94	$	9.12	$	4.95	$	4.59	$	14.89	$	13.71
Diluted	$	5.20	$	4.88	$	9.91	$	9.10	$	4.94	$	4.58	$	14.86	$	13.68

Incremental shares from stock options and restricted stock units were included in the calculation of weighted average diluted shares outstanding using the treasury stock method. Potential dilutive securities have been excluded when their inclusion would be anti-dilutive.

(4) Investments

As of ~~June~~September 30, 2022, we held investments in commercial paper, bonds, money market accounts, mutual funds, and equity securities. The commercial paper and bonds are considered held-to-maturity and are recorded at amortized cost in the accompanying consolidated balance sheets. The money market accounts, equity securities, and mutual funds are recorded at fair value in the accompanying consolidated balance sheets. The fair values of these investments were estimated using recently executed transactions and market price quotations. We consider as current assets those investments which will mature in the next 12 months including interest receivable on the long-term bonds. The remaining investments are considered non-current assets including our investments in equity securities we intend to hold longer than 12 months.

910

Table of Contents

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The components of the ~~Company’s~~Company’s cash and cash equivalents and our ~~short-~~short and long-term investments are as follows (in thousands):

	June 30, 2022			December 31, 2021			September 30, 2022			December 31, 2021
Cash and cash equivalents:
Money market funds	$	6,979		$	29,876		$	26,277		$	29,876
Commercial paper		7,841			0
Cash deposits		1,617			2,388			848			2,388
Total cash and cash equivalents	$	16,437		$	32,264		$	27,125		$	32,264

Short-term investments:
Commercial paper (held-to-maturity)	$	20,495		$	2,248		$	10,094		$	2,248
Bonds (held-to-maturity)		13,418			26,831			10,033			26,831
Equity securities (available for sale)		243			0			171			-
Allowance for credit losses		(10	)		(20	)		(2	)		(20	)
Total short-term investments	$	34,146		$	29,059		$	20,296		$	29,059

Long-term investments:
Equity securities (available for sale)							$	5,665		$	5,468
Bonds (held-to-maturity)	$	10,586		$	13,405			5,129			13,405
Equity securities (available for sale)		4,828			5,468
Mutual funds (available for sale)		385			559			339			559
Allowance for credit losses		(5	)		(9	)		-			(9	)
Total long-term investments	$	15,794		$	19,423		$	11,133		$	19,423

Total cash, cash equivalents and short and long-term investments	$	66,377		$	80,746		$	58,554		$	80,746

We utilize a lifetime ~~“expected~~“expected credit ~~loss”~~loss” measurement objective for the recognition of credit losses for held-to-maturity securities at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. Our credit loss calculations for held-to-maturity securities are based upon historical default and recovery rates of bonds rated with the same rating as our portfolio. We also apply an adjustment factor to these credit loss calculations based upon our assessment of the expected impact from current economic conditions on our investments. We monitor the credit quality of debt securities classified as held-to-maturity through the use of their respective credit ratings and update them on a quarterly basis with our latest assessment completed on ~~June~~September 30, 2022. During the ~~second~~third quarter of 2022, our allowance for credit losses related to short-term investments decreased by $3$8 thousand and our allowance for credit losses related to long-term investments decreased by $2$5 thousand.

1011

Table of Contents

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The following table summarizes the amortized cost of our held-to-maturity bonds at ~~June~~September 30, 2022 aggregated by credit quality indicator (in thousands):

~~Held-to-Maturity Bonds~~

Held-to-Maturity Bonds									Held-to-Maturity Bonds
Credit Quality Indicators	Fed Govt. Bonds/Notes		Municipal Bonds		Corporate Bonds		Totals			Fed Govt. Bonds/Notes		Municipal Bonds		Corporate Bonds		Totals
AAA/AA/A	$	2,243	$	630	$	8,547	$	11,420		$	213	$	633	$	5,047	$	5,893
BBB/BB		0		0		12,585		12,585			-		-		9,269		9,269
TOTAL	$	2,243	$	630	$	21,132	$	24,005		$	213	$	633	$	14,316	$	15,162

Our investments are required to be measured for disclosure purposes at fair value on a recurring basis. Our investments are considered Level 1 or Level 2 as detailed in the table below. The fair values of these investments were estimated using recently executed transactions and market price quotations. The amortized cost and fair value of our investments, and the related gross unrealized gains and losses, were as follows as of the dates shown below (in thousands):

				Gross Unrealized											Gross Unrealized
	Level	Cost		Gains		Losses			Fair Value		Level		Cost		Gains		Losses			Fair Value
As of June 30, 2022:
As of September 30, 2022:
Money market	1		6,979	$	0	$	0		$	6,979		1		26,277	$	-	$	-		$	26,277
Commercial paper	2		28,337	$	0	$	(37	)	$	28,300		2		10,094	$	-	$	(21	)	$	10,073
Bonds	2		24,005	$	2	$	(275	)	$	23,732		2		15,162	$	-	$	(256	)	$	14,906
Mutual funds	1		476	$	0	$	(91	)	$	385		1		444	$	-	$	(105	)	$	339
Equity investments	2		6,054	$	0	$	(983	)	$	5,071		2		6,054	$	-	$	(218	)	$	5,836

As of December 31, 2021:
Money Market	1		29,876	$	0	$	0		$	29,876		1		29,876	$	-	$	-		$	29,876
Commercial paper	2		2,248	$	0	$	0		$	2,248		2		2,248	$	-	$	-		$	2,248
Bonds	2		40,236	$	97	$	(37	)	$	40,296		2		40,236	$	97	$	(37	)	$	40,296
Mutual funds	1		558	$	1	$	0		$	559		1		558	$	1	$	-		$	559
Equity investments	2		5,675	$	0	$	(207	)	$	5,468		2		5,675	$	-	$	(207	)	$	5,468

The carrying value of our investments is reviewed quarterly for changes in circumstances or the occurrence of events that suggests an investment may not be fully recoverable. The bonds represent investments in various issuers at ~~June~~September 30, 2022. The unrealized losses for some of these bond investments reflect changes in interest rates following their acquisition. As of ~~June~~September 30, 2022, we had six bond investments in a loss position for more than 12 months.

At ~~June~~September 30, 2022, the length of time until maturity of the commercial paper we owned ranged from less than a month to ~~six~~three months and the length of time to maturity for the bonds ranged from less than a month to 4239 months.

~~As of June 30, 2022, there were expenditures of $2.4 million related to property, plant, and equipment included in our accounts payable and accrued liabilities balance.~~

1112

Table of Contents

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

As of September 30, 2022, there were expenditures of $2.1 million related to property, plant, and equipment included in our accounts payable and accrued liabilities balance.

(5) Patents and Licenses

Patents and license fees paid for the use of other ~~entities’~~entities’ patents are amortized over the useful life of the patent or license. The following tables provide information regarding patents and licenses (dollars in thousands):

June 30, 2022

December 31, 2021

Weighted Average
Original Life
(years)

Gross
Carrying
Amount

Accumulated
Amortization

Weighted Average
Original Life
(years)

Gross
Carrying
Amount

Accumulated
Amortization

15.67

$ 13,840

$ 12,598

15.67

$ 13,840

$ 12,538

September 30, 2022

December 31, 2021

Weighted Average

Original Life

(years)

Gross

Carrying

Amount

Accumulated

Amortization

Weighted Average

Original Life

(years)

Gross

Carrying

Amount

Accumulated

Amortization

15.67

13,840

12,627

15.67

13,840

12,538

Aggregated amortization expense for patents and licenses was ~~$30~~$29 thousand in ~~each of~~ the three-month ~~periods~~period ended ~~June~~September 30, 2022 and ~~2021 and $60~~$30 thousand for the three-month period ended September 30, 2021. For the nine-month period ended September 30, 2022, the amortization expense was $89 thousand as compared to $90 thousand in ~~each of~~ the ~~six month periods~~nine-month period ended ~~June~~September 30, ~~2022 and~~ 2021.

Estimated future amortization expense for each of the years set forth below ending December 31 is as follows (in thousands):

2023	$	113	$	113
2024	$	113	$	113
2025	$	112	$	112
2026	$	112	$	112
2027	$	108	$	108

(6) Revenues

We recognize revenue when performance obligations under the terms of a contract with our customer are satisfied. This occurs with the transfer of control of our products to customers when products are shipped. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services. Sales and other taxes we may collect concurrent with revenue-producing activities are excluded from revenue.

A summary of revenue by geographic area, based on shipping destination, for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 is as follows (in thousands):

	Three Months Ended				Six Months Ended				Three Months Ended				Nine Months Ended
	June 30,				June 30,				September 30,				September 30,
	2022		2021		2022		2021		2022		2021		2022		2021
United States	$	29,346	$	24,649	$	56,341	$	46,687	$	27,779	$	25,447	$	84,121	$	72,134
European Union		8,142		7,987		17,479		15,751		6,371		7,370		23,851		23,121
All other regions		11,394		10,057		22,200		19,424		10,481		10,038		32,679		29,461
Total	$	48,882	$	42,693	$	96,020	$	81,862	$	44,631	$	42,855	$	140,651	$	124,716

1213

Table of Contents

ATRION CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

A summary of revenue by product line for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 is as follows (in thousands):

	Three Months Ended				Six Months Ended				Three Months Ended				Nine Months Ended
	June 30,				June 30,				September 30,				September 30,
	2022		2021		2022		2021		2022		2021		2022		2021
Fluid Delivery	$	21,556	$	20,920	$	45,670	$	39,995	$	19,303	$	19,024	$	64,973	$	59,013
Cardiovascular		18,082		13,157		33,385		25,987		16,780		16,064		50,165		42,051
Ophthalmology		1,804		2,102		2,888		3,796		1,607		1,192		4,495		4,987
Other		7,440		6,514		14,077		12,084		6,941		6,575		21,018		18,665
Total	$	48,882	$	42,693	$	96,020	$	81,862	$	44,631	$	42,855	$	140,651	$	124,716

More than 99 percent of our total revenue in the periods presented herein is pursuant to shipments initiated by a purchase order (our ~~“contract”~~“contract”) and recognized at a single point in time when the performance obligation of the product being shipped is satisfied, rather than recognized over time, and is presented as a receivable on the balance sheet. Payment is typically due within 30 days.

We maintain an allowance for doubtful accounts to reflect estimated losses resulting from the failure of customers to make required payments. We calculate our credit loss allowance for our trade receivables following a lifetime ~~“expected~~“expected credit ~~loss”~~loss” measurement objective. An account is written off when we determine the receivable will not be collected. Historically, bad debt has been immaterial.

We have elected to recognize the cost of shipping as an expense in cost of sales when control over the product has transferred to the customer.

We do not make any material accruals for product returns and warranty obligations because our returns and warranty obligations have been very low due to our focus on quality control.

We do not disclose the value of unsatisfied performance obligations for contracts for which we recognize revenue at the amount for which we have the right to invoice. We believe that the complexity added to our disclosures by the inclusion of a large amount of insignificant detail in attempting to disclose information about immaterial contracts would potentially obscure more useful and important information.

(7) Recent Accounting Pronouncements

From time to time, new accounting pronouncements applicable to us are issued by the Financial Accounting Standards Board or other standards-setting bodies. We generally adopt these standards as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.

1314

Table of Contents

Item 2. ~~Management’s~~Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Overview

We develop and manufacture products primarily for medical applications. We market components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics, and other treatment centers. Our medical products primarily serve the fluid delivery, cardiovascular, and ophthalmology markets. Our other medical and non-medical products include instrumentation and disposables used in valves and inflation devices used in marine and aviation safety products.

Our products are used in a wide variety of applications by numerous customers. We encounter competition in all of our markets and compete primarily on the basis of product quality, price, engineering, customer service, and delivery time.

Our business strategy is to provide hospitals, physicians, and other healthcare providers with the tools they need to improve the lives of the patients they serve. To do so, we provide a broad selection of products in the areas of our expertise. We have diverse product lines serving primarily the fluid delivery, cardiovascular, and ophthalmic markets, and this diversity has served us well as we encounter changing market conditions. Research and development, or R~~&D,~~&D, efforts are focused on improving current products and developing highly-engineered products that meet customer needs and serve niche markets with meaningful sales potential. Proposed new products may be subject to regulatory clearance or approval prior to commercialization and the time period for introducing a new product to the marketplace can be unpredictable. We also focus on controlling costs by investing in modern manufacturing technologies and controlling purchasing processes. We have been successful in consistently generating cash from operations and have used that cash to reduce or eliminate indebtedness, to fund capital expenditures, to make investments, to repurchase stock, and to pay dividends.

Our strategic objective is to further enhance our position in our served markets by:

	··	Focusing on customer needs;
	··	Expanding existing product lines and developing new products;
	··	Maintaining a culture of controlling cost; and
	··	Preserving and fostering a collaborative, entrepreneurial management structure.

For the three months ended ~~June~~September 30, 2022, we reported revenues of ~~$48.9~~$44.6 million, up 144 percent, operating income of ~~$11.0~~$9.6 million, up 131 percent, and net income of ~~$9.3~~$8.8 million, up 57 percent from the three months ended ~~June~~September 30, 2021.

Results for the three months ended ~~June~~September 30, 2022

Consolidated net income totaled ~~$9.3~~$8.8 million, or ~~$5.21~~$4.95 per basic and ~~$5.20~~$4.94 per diluted share, in the ~~second~~third quarter of 2022. This is compared with consolidated net income of ~~$8.9~~$8.3 million, or ~~$4.89~~$4.59 per basic and ~~$4.88~~$4.58 per diluted share, in the ~~second~~third quarter of 2021. The income per basic share computations are based on weighted average basic shares outstanding of ~~1,794~~1,786 thousand in the 2022 period and ~~1,826~~1,803 thousand in the 2021 period. The income per diluted share computations are based on weighted average diluted shares outstanding of ~~1,798~~1,788 thousand in the 2022 period and ~~1,828~~1,806 thousand in the 2021 period.

~~Table of Contents~~

Consolidated revenues of $48.9 million for the second quarter of 2022 were 14.5 percent higher than revenues of $42.7 million for the second quarter of 2021. Our second quarter 2022 results were favorably impacted by a 37% increase in Cardiovascular revenues compared to the second quarter of 2021.

~~Revenues by product line were as follows (in thousands):~~

Three Months Ended
June 30,

2022

2021

Fluid Delivery

$ 21,556

$ 20,920

Cardiovascular

18,082

13,157

Ophthalmology

1,804

2,102

Other

7,440

6,514

Total

$ 48,882

$ 42,693

Cost of goods sold of $28.0 million for the second quarter of 2022 was 13 percent higher than our cost of goods sold of $24.8 million for the second quarter of 2021, primarily due to higher sales volumes. Our cost of goods sold in the second quarter of 2022 was 57.4 percent of revenue compared to 58.2 percent of revenue in the second quarter of 2021.

Gross profit of $20.8 million in the second quarter of 2022 was $3.0 million or 16.6 percent higher than in the comparable 2021 period. Our gross profit percentage in the second quarter of 2022 was 42.6 percent of revenues compared with 41.8 percent of revenues in the second quarter of 2021. The increase in gross profit percentage in the 2022 period compared to the 2021 period was related to increases in sales of higher margin products, improvements in pricing, and improved efficiency in our manufacturing processes.

Our second quarter 2022 operating expenses of $9.8 million were $1.7 million higher than the operating expenses for the second quarter of 2021. This increase was attributable to an $869 thousand increase in general and administrative expenses, primarily for compensation and depreciation, a $755 thousand increase in selling expenses, primarily for compensation and commissions, and a $108 thousand increase in R&D expenses, primarily for supplies.

Operating income of $11 million in the second quarter of 2022 represented a $1.2 million, or 12.6 percent, increase in operating income over second quarter 2021 operating income. This increase was due to higher sales and gross profit discussed above, partially offset by higher operating expenses. Operating income was 22.6 percent of revenues for the second quarter of 2022 and 22.9 percent of revenues for the second quarter of 2021.

Table of Contents

Consolidated revenues of $44.6 million for the third quarter of 2022 were 4 percent higher than revenues of $42.9 million for the third quarter of 2021. Our third quarter 2022 results were favorably impacted by revenue increases in all product lines, including a 4% increase in Cardiovascular revenues, compared to the third quarter of 2021.

Revenues by product line were as follows (in thousands):

	Three Months Ended September 30,
	2022		2021

Fluid Delivery	$	19,303	$	19,024
Cardiovascular		16,780		16,064
Ophthalmology		1,607		1,192
Other		6,941		6,575
Total	$	44,631	$	42,855

Cost of goods sold of $27.0 million for the third quarter of 2022 was 8 percent higher than our cost of goods sold of $25.1 million for the third quarter of 2021, due to higher sales volumes and higher manufacturing costs. Our cost of goods sold in the third quarter of 2022 was 60.4 percent of revenue compared to 58.5 percent of revenue in the third quarter of 2021.

Gross profit of $17.7 million in the third quarter of 2022 was down $137 thousand or 1 percent versus the comparable 2021 period. Our gross profit percentage in the third quarter of 2022 was 39.6 percent of revenues compared with 41.5 percent of revenues in the third quarter of 2021. The decrease in gross profit percentage in the 2022 period compared to the 2021 period was related to higher manufacturing costs.

Our third quarter 2022 operating expenses of $8.1 million were $262 thousand lower than the operating expenses for the third quarter of 2021. This decrease was attributable to a $345 thousand decrease in general and administrative expenses, primarily for compensation, and a $142 thousand decrease in R&D expenses, primarily related to outside services. These were partially offset by an increase in selling expenses of $225 thousand primarily related to compensation.

Operating income of $9.6 million in the third quarter of 2022 represented a $125 thousand, or 1.3 percent, increase in operating income over third quarter 2021 operating income. This increase was due to higher sales and lower operating expenses, partially offset by higher cost of goods sold. Operating income was 21.5 percent of revenues for the third quarter of 2022 and 22.1 percent of revenues for the third quarter of 2021.

Interest and dividend income in the ~~second~~third quarter of 2022 was ~~$292~~$210 thousand compared with ~~$183~~$281 thousand for the same period in the prior year. The ~~increase in interest and~~decrease was attributable to a dividend ~~income~~that was ~~due to dividends~~ received on equity ~~investments.~~investments in the third quarter of 2021 that was not received in the same period of 2022.

Table of Contents

Other investment income in the ~~second~~third quarter of 2022 was a ~~$308~~$764 thousand ~~loss~~gain compared with ~~Other investment income~~a loss of ~~$963~~$173 thousand in the ~~second~~third quarter of 2021. These amounts were attributable to unrealized gains and losses on equity investments resulting from changes in the market values of the investments in each quarter.

Income tax expense was $1.7 million for ~~second~~third quarter of 2022 compared with ~~$2.0~~$1.3 million for the ~~second~~third quarter of 2021. The effective tax rate for the ~~second~~third quarter of 2022 was ~~15.6~~16.5 percent compared with ~~18.4~~13.7 percent for the ~~second~~third quarter of 2021. The ~~decrease~~increase in the ~~second~~third quarter 2022 period effective tax rate was primarily related to ~~increased~~the timing of recognition for tax benefits for sales outside the United States under the foreign derived intangible income deduction as well as the R&D&D tax credit.

Results for the ~~six~~nine months ended ~~June~~September 30, 2022

Consolidated net income totaled ~~$17.8~~$26.7 million, or ~~$9.94~~$14.89 per basic and ~~$9.91~~$14.86 per diluted share, in first ~~six~~nine months of 2022. This is compared with consolidated net income of ~~$16.7~~$24.9 million, or ~~$9.12~~$13.71 per basic and ~~$9.10~~$13.68 per diluted share, in the first ~~six~~nine months of 2021. The income per basic share computations are based on weighted average basic shares outstanding of ~~1,796~~1,793 thousand in the 2022 period and ~~1,826~~1,818 thousand in the 2021 period. The income per diluted share computations are based on weighted average diluted shares outstanding of ~~1,800~~1,796 thousand in the 2022 period and ~~1,830~~1,822 thousand in the 2021 period.

Consolidated revenues of ~~$96.0~~$140.7 million for the first ~~six~~nine months of 2022 were ~~17.3~~12.8 percent higher than revenues of ~~$81.9~~$124.7 million for the first ~~six~~nine months of 2021. This increase in revenue was primarily due to increased sales volumes in our Cardiovascular, Fluid Delivery, and Other product lines.

Revenues by product line were as follows (in thousands):

	Six Months Ended June 30,				Nine Months Ended September 30,
	2022		2021		2022		2021

Fluid Delivery	$	45,670	$	39,995	$	64,973	$	59,013
Cardiovascular		33,385		25,987		50,165		42,051
Ophthalmology		2,888		3,796		4,495		4,987
Other		14,077		12,084		21,018		18,665
Total	$	96,020	$	81,862	$	140,651	$	124,716

Cost of goods sold of ~~$55.9~~$82.9 million for the first ~~six~~nine months of 2022 was ~~$8.3~~$10.2 million higher than in the comparable 2021 period. This increase was mainly due to higher sales volumes. Our cost of goods sold in the first ~~six~~nine months of 2022 was ~~58.3~~59.0 percent of revenues compared to ~~58.2~~58.3 percent of revenues in the first ~~six~~nine months of 2021.

Gross profit was $57.7 million in the first nine months of 2022 and $52.0 million in the first nine months of 2021. Our gross profit percentage was 41.0 percent of revenues in the first nine months in 2022 and 41.7 percent in 2021. This decrease was driven by higher manufacturing costs.

1617

Table of Contents

Gross profit was $40.0 million in the first six months of 2022 and $34.2 million in the first six months of 2021. Our gross profit percentage was 41.7 percent of revenues in the first six months in 2022 and 41.8 percent in 2021.

Operating expenses of ~~$18.8~~$26.8 million for the first ~~six~~nine months of 2022 were ~~$3.3~~$3.1 million higher than the operating expenses for the first ~~six~~nine months of 2021. This increase was attributable to a ~~$1.798~~$1.6 million increase in selling expenses, primarily for compensation, a $1.5 million increase in general and administrative expenses, primarily for compensation, and ~~depreciation,~~ a ~~$1.35 million increase in selling expenses, primarily for compensation and travel costs, and a $174~~$33 thousand increase in R&D&D expenses, primarily for supplies.

Operating income of ~~$21.3~~$30.9 million for the first ~~six~~nine months of 2022 represented a ~~$2.6~~$2.7 million, or 149.5 percent increase, in operating income from the first ~~six~~nine months of ~~2022.~~2021. Operating income was ~~22.2~~22.0 percent of revenues for the first ~~six~~nine months of 2022 and ~~22.9~~22.6 percent of revenues for the first ~~six~~nine months of 2021.

Interest and dividend income for the first ~~six~~nine months of 2022 was ~~$429~~$639 thousand, compared with ~~$399~~$680 thousand for the same period in the prior year. The ~~increase~~decrease in interest and dividend income was primarily due to ~~dividends~~lower interest income received on ~~equity~~ investments.

Other investment income for the first ~~six~~nine months of 2022 was a ~~$548~~$216 thousand ~~loss~~gain compared to ~~$1.0 million~~an $852 thousand gain in the first ~~six~~nine months of 2021. These amounts were attributable to unrealized gains and losses on equity investments resulting from changes in the market values of our investments in each time period.

Income tax expense was ~~$3.4~~$5.1 million for the first ~~six~~nine months in 2022 and ~~$3.6~~$4.9 million for the first ~~six~~nine months in 2021. The effective tax rate for the first ~~six~~nine months of 2022 was ~~16.0~~16.2 percent, compared with ~~17.6~~16.4 percent for the first ~~six~~nine months of 2021. The decrease in the 2022 period effective tax rate was primarily related to increased tax benefits for sales outside the United States under the foreign derived intangible income deduction as well as the R&D tax credit. We expect the effective tax rate for 2022 to be approximately 1716 percent.

Liquidity and Capital Resources

As of ~~June~~September 30, 2022, we had a $75.0 million revolving credit facility with a money center bank pursuant to which the lender is obligated to make advances until February 28, 2024. The credit facility is secured by substantially all of our inventories, equipment, and accounts receivable. Interest under the credit facility is assessed at 30-day, 60-day or 90-day LIBOR, as selected by us, plus 1.0 percent and is payable monthly. We had no outstanding borrowings under the credit facility at ~~June~~September 30, 2022 and we were in compliance with all financial covenants.

At ~~June~~September 30, 2022, we had a total of ~~$66.4~~$58.6 million in cash and cash equivalents, short-term investments, and long-term investments. At December 31, 2021, cash and cash equivalents, short-term investments, and long-term investments totaled $80.7 million.

Cash flows from operating activities of ~~$18.3~~$28.9 million for the ~~six~~nine months ended ~~June~~September 30, 2022 were primarily comprised of net income plus the net effect of non-cash expenses and an increase in ~~accounts payable.~~inventory. During the first ~~six~~nine months of 2022, we used ~~$22.3~~$25.5 million for the purchase of investments, ~~$15.2~~$25.3 million for the addition of property and equipment, ~~$7.0~~$10.8 million for dividends, and ~~$9.3~~$14.4 million for the purchase of treasury stock. During the same period, maturities and sales of investments generated ~~$20.2~~$42.7 million in cash. For the ~~six~~nine months ended ~~June~~September 30, 2021, cash flows from operating activities of ~~$16.0~~$28.8 million were primarily comprised of net income plus the net effect of non-cash expenses, ~~offset by~~ increases in accounts ~~receivable.~~receivable, and prepaid expenses. During the first ~~six~~nine months of 2021, we used ~~$16.1~~$18.1 million for the purchase of investments ~~$7.3~~and $11.6 million for the addition of property and equipment, ~~$10.5~~$9.9 million for dividends, and $17.0 million for the purchase of treasury ~~stock and $6.4 million for dividends.~~stock. During the same period, maturities and sales of investments generated ~~$19.4~~$29.4 million in cash.

1718

Table of Contents

At ~~June~~September 30, 2022, we had working capital of ~~$118.3~~$114.8 million, including ~~$16.4~~$27.1 million in cash and cash equivalents and ~~$34.1~~$20.3 million in short-term investments, compared to working capital of $123.2 million at December 31, 2021. The ~~$4.9~~$8.4 million decrease in working capital during the first ~~six~~nine months of 2022 was primarily related to an increase in ~~accounts payable and accrued expenses~~current liabilities of ~~$4.8~~$4.5 million.

We believe that our ~~$66.4~~$58.6 million in cash, cash equivalents, short-term investments, and long-term investments, along with cash flows from operations and available borrowings of up to $75.0 million under our credit facility, will be sufficient to fund our cash requirements for at least the foreseeable future, including the costs associated with the expansion of one of our manufacturing facilities. We believe that our strong financial position would allow us to access equity or debt financing should that be necessary.

COVID-19 Impact

The COVID-19 pandemic ~~continues to impact~~has impacted the global economy ~~cause~~and our business, caused market instability and uncertainty in the labor market, and put pressure on supply chains and healthcare ~~systems,~~systems. Even with the public health actions that have been taken to reduce the spread and ~~it has impacted,~~severity of the virus, the global economy and ~~will likely~~markets continue to ~~impact, our business. The pandemic continues to evolve~~experience disruptions, and the ~~full extent~~virus may continue to pose future risks with the emergence of ~~its impact will depend on future developments, which are highly uncertain and cannot be determined at this time.~~new variants. We will continue to monitor the COVID-19 pandemic as well as resulting legislative and regulatory changes to manage our response and assess and seek to mitigate potential adverse impacts on our business. For additional discussion regarding the COVID-19 pandemic and our related risks, see Part I, Item 1A, ~~“Risk Factors”~~“Risk Factors” included in our 2021 Form 10-K.

Forward-Looking Statements

Statements in this ~~Management’s~~Management’s Discussion and Analysis and elsewhere in this Quarterly Report on Form 10-Q that are ~~forward looking~~forward-looking are based upon current expectations, and actual results or future events may differ materially. Therefore, the inclusion of such forward-looking information should not be regarded as a representation by us that our objectives or plans will be achieved. Such statements include, but are not limited to, our effective income tax rate for 2022, our ability to fund our cash requirements for the foreseeable future with our current assets, long-term investments, cash flow, and borrowings under the credit facility, and our access to equity and debt ~~financing, and the impact of the COVID-19 pandemic on our business.~~financing. Words such as ~~“expects,” “believes,” “anticipates,” “intends,” “should,” “plans,”~~“expects,” “believes,” “anticipates,” “intends,” “should,” “plans,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that the COVID-19 pandemic leads to further material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 pandemic; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 pandemic further disrupts local economies and causes economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The forward-looking statements in this Quarterly Report on Form 10-Q are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

For the quarter ended ~~June~~September 30, 2022, we did not experience any material changes in market risk exposures that affect the quantitative and qualitative disclosures presented in our 2021 Form 10-K.

Item 4. Controls and Procedures.

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of ~~June~~September 30, 2022. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting for the quarter ended ~~June~~September 30, 2022 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

1819

Table of Contents

PART II - OTHER INFORMATION

~~Item~~ITEM 1.Legal Proceedings.

We have no pending legal proceedings of the type described in Item 103 of Regulation S-K.

~~Item~~ITEM 1A.Risk Factors.

As of the date of this Report, there has been no material change in the risk factors described in our 2021 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

The table below sets forth information with respect to our purchases of our common stock during each month in the three month period ended ~~June~~September 30, 2022.

Period

Total Number of Shares Purchased

Average Price Paid per Share

Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs

Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs ⁽¹⁾

4/1/2022 to 4/30/2022

-

-

-

168,553

5/1/2022 to 5/31/2022

3,557

$ 619.41

3,557

164,996

6/1/2022 to 6/30/2022

5,969

$ 618.19

5,969

159,027

Total

9,526

$ 618.65

9,526

159,027

Period	Total Number of Shares Purchased		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs ⁽¹⁾
7/1/2022 to 7/31/2022		1,997	$	621.34		1,997		157,030
8/1/2022 to 8/31/2022		1,284	$	608.84		1,284		155,746
9/1/2022 to 9/30/2022		5,296	$	579.21		5,296		150,450
Total		8,577	$	593.46		8,577		150,450

(1)

On May 21, 2015, our Board of Directors approved a stock repurchase program pursuant to which we can repurchase up to 250,000 shares of our common stock from time to time in open market or privately-negotiated transactions. At ~~June~~September 30, 2022, we had repurchased ~~90,973~~99,550 shares of our common stock authorized under the program approved in May 2015. Our stock repurchase program has no expiration date but may be terminated by our Board of Directors at any time.

1920

Table of Contents

Item 6. Exhibits.

Exhibit Index

Exhibit
Number		Description
~~10.1~~		~~Retirement Agreement between Atrion Corporation and Jeffery Strickland dated July 29, 2022~~

31.1		Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer

31.2		Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer

32.1		Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes –– Oxley Act Of 2002

32.2		Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes –– Oxley Act Of 2002

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

2021

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	~~Atrion Corporation~~ ~~(Registrant)~~

~~Date: August 8, 2022~~	~~By:~~	~~/s/ David A. Battat~~
	Atrion Corporation (Registrant)		~~David A. Battat~~
		~~President and~~
		~~Chief Executive Officer~~

Date: ~~August~~November 8, 2022	By:	/s/ David A. Battat
		David A. Battat
		President and Chief Executive Officer

Date: November 8, 2022	By:	/s/ Jeffery Strickland
		Jeffery Strickland
		Vice President and
		Chief Financial Officer
		(Principal Accounting and Financial Officer)

2122

	June 30, 2022			December 31, 2021
Assets	(in thousands)
Current assets:
Cash and cash equivalents	$	16,437		$	32,264
Short-term investments		34,146			29,059
Accounts receivable		27,539			21,023
Inventories		54,281			50,778
Prepaid expenses and other current assets		5,171			3,447
		137,574			136,571

Long-term investments		15,794			19,423

Property, plant and equipment		249,648			233,217
Less accumulated depreciation and amortization		140,842			135,245
		108,806			97,972

Other assets and deferred charges:
Patents		1,242			1,302
Goodwill		9,730			9,730
Other		2,171			2,266
		13,143			13,298

Total assets	$	275,317		$	267,264

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities	$	17,861		$	13,076
Accrued income and other taxes		1,412			270
		19,273			13,346

Line of credit		0			0

Other non-current liabilities		9,589			9,622

Stockholders’ equity:
Common stock, par value $0.10 per share; authorized 10,000 shares, issued 3,420 shares		342			342
Paid-in capital		66,167			61,174
Retained earnings		368,165			357,324
Treasury shares, 1,632 at June 30, 2022 and 1,619 at December 31, 2021, at cost		(188,219	)		(174,544	)
Total stockholders’ equity		246,455			244,296

Total liabilities and stockholders’ equity	$	275,317		$	267,264